Morphic Corporation: Company Investigated by the Portnoy Law Firm


Investors can contact the law firm at no cost to learn more about recovering their losses

LOS ANGELES, Nov. 06, 2023 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Morphic Holding, Inc. (NASDAQ: MORF) investors that the firm has initiated an investigation into possible securities violations and may file a class action on behalf of investors. Morphic investors that lost money on their investment are encouraged to contact Lesley Portnoy, Esq.

Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 844-767-8529 or email: lesley@portnoylaw.com, to discuss their legal rights, or click here to join the case via www.portnoylaw.com. The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors’ options for pursuing claims to recover their losses.

Morphic Holding, Inc., a biopharmaceutical firm, specializes in identifying and creating oral small-molecule treatments targeting integrins, aimed at managing a spectrum of conditions including autoimmune, cardiovascular, metabolic disorders, fibrosis, and oncological diseases.

In September 2023, the firm disclosed outcomes from a 12-week clinical trial for a severe form of ulcerative colitis. The data revealed that 25.7% of subjects treated with their drug experienced endoscopic amelioration. Subsequent to the announcement, the company's share value experienced a sharp decline of 55%.

Please visit our website to review more information and submit your transaction information.

The Portnoy Law Firm represents investors in pursuing claims against caused by corporate wrongdoing. The Firm’s founding partner has recovered over $5.5 billion for aggrieved investors. Attorney advertising. Prior results do not guarantee similar outcomes.

Lesley F. Portnoy, Esq.
Admitted CA and NY Bar
lesley@portnoylaw.com
310-692-8883
www.portnoylaw.com

Attorney Advertising